# The Emerging Biotech Market for Pet Longevity and Preservation From longevity drugs to cloning, biotech firms are offering new ways to extend pet companionship. - **Source:** [MIT Technology Review](https://www.technologyreview.com) - **Published:** 2026-10-16 - **Topic:** [Business](https://brifing.si/c/business) - **Original article:** - **On Brifing:** https://brifing.si/s/5ca06609-c42c-471a-91cd-c316b044df61 ## Expanding Pet Longevity Market Biotech companies are increasingly targeting the pet care market with innovative life-extension technologies. Firms are developing drugs specifically designed to combat age-related diseases in dogs and cats. These treatments aim to improve metabolic health, potentially delaying conditions like obesity and osteoarthritis, marking a shift toward treating aging as a manageable medical condition. ## Clinical Trials for Dogs The company Loyal is currently conducting trials for longevity drugs involving approximately 1,300 dogs across the United States. These clinical efforts focus on improving metabolic health to extend the lifespan of canine companions. By targeting specific biological markers of aging, these researchers hope to provide tangible health benefits for aging household pets. ## The Science of Cloning Cloning technology allows pet owners to create a genetic twin of their deceased animal. The process involves transferring DNA into an egg cell and using a surrogate animal for gestation. While companies like Viagen Pets offer this service for $50,000, the result is a genetic copy rather than an exact behavioral replica. ## Addressing Disenfranchised Grief Professor Lori Kogan notes that society lacks formal rituals for pet loss, leading to disenfranchised grief. Because pet owners often feel their sorrow is unrecognized, services like cloning may provide a sense of peace. This perspective suggests that such technologies serve an emotional function for those struggling with the isolation of loss. ## Developmental Impact of Loss Childhood experiences with pet loss often serve as a formative introduction to the finality of death. Confronting this reality can help individuals process future losses during adulthood. There are concerns that replacing pets through cloning might distort a child's understanding of mortality, potentially complicating their emotional development regarding life and death cycles. ## Cryonics and Future Hopes Cryonics facilities like Alcor offer to store deceased pets at extremely low temperatures for indefinite periods. The premise relies on the hope that future technology will eventually enable reanimation and disease curing. Recently, the facility even cooled a sugar glider, marking an expansion of these services beyond traditional cats and dogs. ## Technical Reality of Reanimation Despite the promises made by cryonics providers, the scientific probability of reuniting with a preserved pet remains near zero. Industry professionals acknowledge that reanimation is currently impossible with existing technology. These services operate on speculative future advancements rather than established medical capabilities, leaving the actual outcome for stored remains highly uncertain. ## Ethical and Practical Limits While biotech offers diverse options for pet preservation, the industry faces significant ethical and practical scrutiny. From the high costs of cloning to the speculative nature of cryonics, these services highlight the complex intersection of grief and technology. Ultimately, the market reflects a growing human desire to defy the natural finality of loss. ## Sources covering this story - https://www.technologyreview.com/2026/10/16/1146766/pet-biotech-longevity-cloning-cryonics/ — --- _Summary written by Brifing from the original reporting. Copyright in the original article belongs to its publisher; read the full piece at the link above._